Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMLN (DIABETES DRUGS) -- Ignore unavailable to you. Want to Upgrade?

To: schadenfreude who wrote (963)	11/20/1997 1:38:00 PM
From: D.Right	Read Replies (1) \| Respond to of 2173

Dear J Kniss: Well, I don't know how Barron calculated its figures. Let's just say the number is right. For $2-3 earnings, a P/E of 10 is $20-30, a P/E of 20 is $40-60 and a P/E of 30 is $60-90. The average P/E for most of the profit-generating biotech companies is very high because the patent deos protect the monopoly for many years (I have to check the exact years) from the day the drug is marketed. Good Day D.Right

To: schadenfreude who wrote (963)	11/20/1997 2:24:00 PM
From: Andrew H	Read Replies (1) \| Respond to of 2173

Almost all of Murphy's long term biotech predictions are all wet. A few years ago he was prediction that many of these stocks would already be at 100! Its really a joke. As for AMLN, it is likely to be dead money or worse for quite a while here. However, I would be a buyer at 4, since there is a reasonable possibility that pramlintide will eventually be approved. By the time it is, there will most likely be a number of treatments available for Type 11, but Type I is still a large market.